Could 2 years of hormone therapy be enough for some breast cancers?
NCT ID NCT07153757
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a shorter course of hormone therapy (2-3 years) works as well as the standard longer treatment for women with a very low-risk, early-stage breast cancer. About 2,900 women will be randomly assigned to either the shorter or standard treatment. The goal is to see if the shorter option can maintain cancer control while reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- endocrine therapy (hormone-blocking drugs like tamoxifen or aromatase inhibitors)
- What this could lead to
- If successful, this could show that many women with low-risk breast cancer can safely stop hormone therapy after 2-3 years, reducing side effects and improving quality of life.
- What could go wrong
- This is a large phase 3 trial, but it only includes very low-risk patients, so results may not apply to others. There is a small chance that shorter therapy could lead to higher recurrence rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
270 Dongan Road, Fudan University Shanghai Cancer Center
Shanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise during chemo: a new weapon to preserve strength?
- Could a smartphone program ease Chemo's emotional toll?
- Could fewer heart tests be safer for breast cancer patients?
- New study aims to predict who will respond to breast cancer therapy
- Blood test could revolutionize breast cancer monitoring
- Tech trio aims to help breast cancer survivors remember daily pills